Latest & greatest articles for escitalopram

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on escitalopram or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on escitalopram and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for escitalopram

1. A systematic review of escitalopram in the treatment of children and adolescents with major depressive disorder

A systematic review of escitalopram in the treatment of children and adolescents with major depressive disorder Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

2. Escitalopram

Escitalopram Top results for escitalopram - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for escitalopram The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

3. Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. (PubMed)

Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. Depression has been associated with poorer medical outcomes in acute coronary syndrome (ACS), but there are few data on the effects of antidepressant treatment on long-term prognosis.To investigate the effect on long-term major adverse cardiac events (MACE) of escitalopram treatment of depression in patients with recent ACS.Randomized (...) , double-blind, placebo-controlled trial conducted among 300 patients with recent ACS and depression enrolled from May 2007 to March 2013, with follow-up completed in June 2017, at Chonnam National University Hospital, Gwangju, South Korea.Patients were randomly assigned to receive either escitalopram in flexible dosages of 5, 10, 15, or 20 mg/d (n = 149) or matched placebo (n = 151) for 24 weeks.The primary outcome was MACE, a composite of all-cause mortality, myocardial infarction (MI

2018 JAMA Controlled trial quality: predicted high

4. Randomised controlled trial of escitalopram for cervical dystonia with dystonic jerks/tremor

Randomised controlled trial of escitalopram for cervical dystonia with dystonic jerks/tremor Trials for additional or alternative treatments for cervical dystonia (CD) are scarce since the introduction of botulinum neurotoxin (BoNT). We performed the first trial to investigate whether dystonic jerks/tremor in patients with CD respond to the selective serotonin reuptake inhibitor (SSRI) escitalopram.In a randomised, double-blind, crossover trial, patients with CD received escitalopram (...) and placebo for 6 weeks. Treatment with BoNT was continued, and scores on rating scales regarding dystonia, psychiatric symptoms and quality of life (QoL) were compared. Primary endpoint was the proportion of patients that improved at least one point on the Clinical Global Impression Scale for jerks/tremor scored by independent physicians with experience in movement disorders.Fifty-threepatients were included. In the escitalopram period, 14/49 patients (29%) improved on severity of jerks/tremor versus 11

2018 EvidenceUpdates

5. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. (PubMed)

Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. We compared transcranial direct-current stimulation (tDCS) with a selective serotonin-reuptake inhibitor for the treatment of depression.In a single-center, double-blind, noninferiority trial involving adults with unipolar depression, we randomly assigned patients to receive tDCS plus oral placebo, sham tDCS plus escitalopram, or sham tDCS plus oral placebo. The tDCS was administered in 30-minute, 2-mA prefrontal (...) stimulation sessions for 15 consecutive weekdays, followed by 7 weekly treatments. Escitalopram was given at a dose of 10 mg per day for 3 weeks and 20 mg per day thereafter. The primary outcome measure was the change in the 17-item Hamilton Depression Rating Scale (HDRS-17) score (range, 0 to 52, with higher scores indicating more depression). Noninferiority of tDCS versus escitalopram was defined by a lower boundary of the confidence interval for the difference in the decreased score that was at least

2017 NEJM Controlled trial quality: predicted high

6. Citalopram and escitalopram: opt for other SSRI antidepressants

Citalopram and escitalopram: opt for other SSRI antidepressants Prescrire IN ENGLISH - Spotlight ''Citalopram and escitalopram: opt for other SSRI antidepressants'', 1 September 2016 {1} {1} {1} | | > > > Citalopram and escitalopram: opt for other SSRI antidepressants Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Citalopram and escitalopram: opt (...) for other SSRI antidepressants As of early 2016, studies point to the same overall conclusion: that citalopram and its derivative escitalopram expose patients to a higher risk of cardiac disorders than other SSRI antidepressants. Citalopram and escitalopram are selective serotonin reuptake inhibitors (SSRI). These two drugs are no more effective than other SSRI antidepressants, and their adverse effects profile is also very similar. In 2011 and 2012, the Food and Drug Administration (FDA) issued

2016 Prescrire

7. Combining escitalopram and cognitive-behavioural therapy for social anxiety disorder: randomised controlled fMRI trial (PubMed)

Combining escitalopram and cognitive-behavioural therapy for social anxiety disorder: randomised controlled fMRI trial Selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioural therapy (CBT) are often used concomitantly to treat social anxiety disorder (SAD), but few studies have examined the effect of this combination.To evaluate whether adding escitalopram to internet-delivered CBT (ICBT) improves clinical outcome and alters brain reactivity and connectivity in SAD.Double (...) -blind, randomised, placebo-controlled neuroimaging trial of ICBT combined either with escitalopram (n = 24) or placebo (n = 24), including a 15-month clinical follow-up (trial registration: ISRCTN24929928).Escitalopram+ICBT, relative to placebo+ICBT, resulted in significantly more clinical responders, larger reductions in anticipatory speech state anxiety at post-treatment and larger reductions in social anxiety symptom severity at 15-month follow-up and at a trend-level (P = 0.09) at post-treatment

Full Text available with Trip Pro

2016 EvidenceUpdates Controlled trial quality: predicted high

8. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. (PubMed)

Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. Depression is frequent in patients with heart failure and is associated with adverse clinical outcomes. Long-term efficacy and safety of selective serotonin reuptake inhibitors in these patients are unknown.To determine whether 24 months of treatment with escitalopram improves mortality, morbidity, and mood in patients with chronic systolic (...) the 9-item Patient Health Questionnaire. Patients with suspected depression were then invited to undergo a Structured Clinical Interview based on the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) to establish the diagnosis.Patients were randomized 1:1 to receive escitalopram (10-20 mg) or matching placebo in addition to optimal heart failure therapy. Study duration was 24 months.The composite primary outcome was time to all-cause death or hospitalization. Prespecified

Full Text available with Trip Pro

2016 JAMA Controlled trial quality: predicted high

9. Analgesic Effect of Perioperative Escitalopram in High Pain Catastrophizing Patients after Total Knee Arthroplasty: A Randomized, Double-blind, Placebo-controlled Trial (PubMed)

Analgesic Effect of Perioperative Escitalopram in High Pain Catastrophizing Patients after Total Knee Arthroplasty: A Randomized, Double-blind, Placebo-controlled Trial Sufficient pain treatment remains a challenge after total knee arthroplasty (TKA), especially in high pain catastrophizing patients. Serotonergic signaling may be involved in pain processing, but the effect of selective serotonin reuptake inhibitors on well-defined postoperative pain has not previously been investigated (...) . The authors hypothesized that perioperative escitalopram would reduce pain after TKA in high pain catastrophizing patients.A total of 120 pain catastrophizing patients (selected using the pain catastrophizing scale as preoperative screening tool) scheduled for TKA were randomized in a double-blind manner to either 10 mg escitalopram or placebo daily from preanesthesia to postoperative day 6 in addition to a standardized analgesic regime. The primary outcome was pain upon ambulation 24 h after surgery

Full Text available with Trip Pro

2015 EvidenceUpdates Controlled trial quality: predicted high

10. Escitalopram

Escitalopram USE OF ESCITALOPRAM IN PREGNANCY 0344 892 0909 USE OF ESCITALOPRAM IN PREGNANCY (Date of issue: January 2017 , Version: 2.2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Escitalopram is a selective serotonin reuptake inhibitor (...) (SSRI) used in the treatment of depression, panic disorder, with or without agoraphobia, generalised and social anxiety disorder, and obsessive-compulsive disorder. Although limited, data on the risk of congenital malformation following escitalopram use in early pregnancy are generally reassuring. The available studies provide no evidence of an increase in overall congenital malformation rate, and the majority of studies investigating specific cardiovascular malformations have failed to identify

2014 UK Teratology Information Service

11. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].

[Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram]. Such a prevalent disease as Major Depressive Disorder (MDD), associated with prominent impairment in physical and social functioning, implies as well an increased morbidity and mortality. Long-term treatments are required due to the frequent occurrence of relapses. Patient compliance is a core factor in both acute and continuation treatment, closely related (...) to tolerability issues. We have partially reviewed the literature published on PubMed since 2004 which assess the relative antidepressant efficacy of escitalopram and comparator antidepressants in adult patients who met DSM-IV criteria for major depressive disorder (MDD). Clinically important differences exist between commonly prescribed antidepressants. These analyses are in favor of a superior efficacy and tolerability of long-term escitalopram treatment (10 to 20mg/day) compared with active controls

2013 L'Encephale

12. Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. (PubMed)

Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. Mental stress can induce myocardial ischemia and also has been implicated in triggering cardiac events. However, pharmacological interventions aimed at reducing mental stress-induced myocardial ischemia (MSIMI) have not been well studied.To examine the effects of 6 weeks of escitalopram treatment vs placebo on MSIMI and other psychological stress-related biophysiological and emotional parameters.The (...) REMIT (Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment) study, a randomized, double-blind, placebo-controlled trial of patients with clinically stable coronary heart disease and laboratory-diagnosed MSIMI. Enrollment occurred from July 24, 2007, through August 24, 2011, at a tertiary medical center.Eligible participants were randomized 1:1 to receive escitalopram (dose began at 5 mg/d, with titration to 20 mg/d in 3 weeks) or placebo over 6 weeks.Occurrence of MSIMI

2013 JAMA Controlled trial quality: predicted high

13. Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs

Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference

2013 Evidence-Based Mental Health

14. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder

Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder Nordstrom G, Danchenko N, Despiegel N (...) , Marteau F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the cost-effectiveness of escitalopram compared with venlafaxine extended release, as first-line treatment for adults with major depressive disorder

Full Text available with Trip Pro

2013 NHS Economic Evaluation Database.

15. Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. (PubMed)

Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. Mental stress can induce myocardial ischemia and also has been implicated in triggering cardiac events. However, pharmacological interventions aimed at reducing mental stress-induced myocardial ischemia (MSIMI) have not been well studied.To examine the effects of 6 weeks of escitalopram treatment vs placebo on MSIMI and other psychological stress-related biophysiological and emotional parameters.The (...) REMIT (Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment) study, a randomized, double-blind, placebo-controlled trial of patients with clinically stable coronary heart disease and laboratory-diagnosed MSIMI. Enrollment occurred from July 24, 2007, through August 24, 2011, at a tertiary medical center.Eligible participants were randomized 1:1 to receive escitalopram (dose began at 5 mg/d, with titration to 20 mg/d in 3 weeks) or placebo over 6 weeks.Occurrence of MSIMI

Full Text available with Trip Pro

2013 JAMA Controlled trial quality: predicted high

16. Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial (PubMed)

Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial To evaluate sexual function in midlife women using selective serotonin reuptake inhibitors for vasomotor symptoms. Selective serotonin reuptake inhibitors effectively treat vasomotor symptoms but adversely affect sexual function in depressed populations. Information on sexual function in nondepressed midlife women using selective serotonin reuptake inhibitors for vasomotor symptoms (...) is lacking; any treatments that might impair function are of concern.This was a randomized controlled trial comparing 8 weeks of escitalopram with placebo in women ages 40-62 years with 28 or more bothersome vasomotor symptoms per week. Change in Female Sexual Function Index composite score (ranges from 2 [not sexually active, no desire] to 36) and six sexual domains (desire, arousal, lubrication, orgasm, satisfaction, pain) and the Female Sexual Distress Scale, and a single-question of sexually-related

Full Text available with Trip Pro

2012 EvidenceUpdates Controlled trial quality: predicted high

17. Efficacy of escitalopram compared to citalopram: a meta-analysis

Efficacy of escitalopram compared to citalopram: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

18. Citalopram and escitalopram: QT interval prolongation

Citalopram and escitalopram: QT interval prolongation Citalopram and escitalopram: QT interval prolongation - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Citalopram and escitalopram: QT interval prolongation New maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Published 11 December 2014 From: Therapeutic area: Contents Article date: December 2011 Citalopram, a racemic mixture of R and S citalopram, is a selective serotonin (...) reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder, panic disorder, and obsessive compulsive disorder. Escitalopram is the S enantiomer of citalopram indicated for major depressive episodes, panic disorder with or without agoraphobia, social anxiety disorder (social phobia), generalised anxiety disorder, and obsessive compulsive disorder. New data for QT prolongation with citalopram and escitalopram The potential for citalopram and escitalopram to cause QT interval

2011 MHRA Drug Safety Update

19. Randomised controlled trial: Escitalopram reduced hot flashes in non-depressed perimenopausal and postmenopausal women

Randomised controlled trial: Escitalopram reduced hot flashes in non-depressed perimenopausal and postmenopausal women Escitalopram reduced hot flashes in non-depressed perimenopausal and postmenopausal women | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Escitalopram reduced hot flashes in non-depressed perimenopausal and postmenopausal women Article Text Therapeutics Randomised controlled trial Escitalopram reduced hot flashes

2011 Evidence-Based Medicine (Requires free registration)

20. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. (PubMed)

Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. Concerns regarding the risks associated with estrogen and progesterone to manage menopausal symptoms have resulted in its declining use and increased interest in nonhormonal treatments with demonstrated efficacy for hot flashes.To determine the efficacy and tolerability of 10 to 20 mg/d escitalopram, a selective serotonin reuptake inhibitor, in alleviating the frequency, severity, and bother (...) of menopausal hot flashes.A multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel group trial that enrolled 205 women (95 African American; 102 white; 8 other) between July 2009 and June 2010.Women received 10 to 20 mg/d of escitalopram or a matching placebo for 8 weeks.Primary outcomes were the frequency and severity of hot flashes assessed by prospective daily diaries at weeks 4 and 8. Secondary outcomes were hot flash bother, recorded on daily diaries, and clinical improvement

Full Text available with Trip Pro

2011 JAMA Controlled trial quality: predicted high